This book brings together mental health professionals and researchers to offer the most up-to-date information on the diagnosis, treatment, and research surrounding bipolar depression. Its individual chapters provide valuable diagnostic information, allowing clinicians to distinguish between the various mood disorders. Further, they: review the course, outcome, and genetics of this highly heritable condition; offer a thorough overview of the neurobiology of the disorder, including what is known from neuroimaging work; delineate the treatment of bipolar depression in special populations such as children and pregnant women; address suicide, focusing on the need for assessment during both acute and maintenance treatment with interventions appropriate to a patient's symptoms and history; and cover acute and long-term treatment strategies for bipolar depression, including both traditional and novel therapeutics for the disorder, as well as non-pharmacological treatments. This second edition reflects significant advances, including an improved understanding of the altered neurobiology of patients suffering from bipolar depression, new information on pathophysiology and genetic findings drawn from diverse studies, and a discussion of the significant strides made towards improved treatment with already available and novel agents.

Enzymes have interesting applications in our biological system and act as valuable biocatalysts. Their various functions allow enzymes to develop new drugs, detoxifications, and pharmaceutical chemistry. Research Advancements in Pharmaceutical, Nutritional, and Industrial Enzymology provides emerging research on biosynthesis, enzymatic treatments, and bioengineering of medicinal waste. While highlighting issues such as structural implications for drug development and food applications, this publication explores information on various applications of enzymes in pharmaceutical, nutritional, and industrial aspects. This book is a valuable resource for medical professionals, pharmacists, pharmaceutical companies, researchers, academics, and upper-level students seeking current information on developing scientific ideas for new drugs and other enzymatic advancements.

This issue of the Clinics in Laboratory Medicine on "Pharmacogenomics" is being edited by Drs. Roland Valdes and Kristen Reynolds and will cover a wide variety of topics, including but not limited to, fundamentals of pharmacology, a review of pharmacogenetics guidelines, pharmacogenetic testing in pain management, pharmacogenetics of pain management, clinical and economic impact of pharmacogenetic genotyping analysis, exosome analysis in lab medicine, and implementation of pharmacogenetics in developing countries.

This book addresses chemical and biological aspects related to sesquiterpene lactones (STLs). Experts in different fields have been invited to contribute on this class of compound's chemistry, isolation and identification, biological activities (antibacterial, antifungal, antiviral, antitrypanosomal, antileishmanial,antiplasmodial, antiproliferative and antiinflammatory), synthesis, biosynthesis, derivatization and QSAR analysis. Taxonomic and chemotaxonomic aspects related to the Asteraceae family are also contributed. The book begins by describing the chemical characteristics of STLs, their classification in different skeleton types, synthesis, distribution in nature and their most important biological properties. An overview of the group's main representatives, based on their importance for human health, as well as an update of the most recently isolated STLs, follow. The authors also provide an overview of the most common methods described in the literature for the extraction, purification, identification and structure elucidation of STLs, while also highlighting more recently developed methods. Furthermore, experts in the field provide an in-depth discussion of the most commonly employed in vitro and in vivo antiprotozoal assays against the different stages of parasites, as well as STLs' properties as anticancer agents in numerous cancer cell lines and animal models. Lastly, the book presents examples of the in vitro and in vivo activity of STLs and their mechanism of antiprotozoal action, together with an analysis of ultrastructural alterations, observed using TEM techniques. The book is aimed at scientists working on natural products: both those investigating this particular group of compounds and those who wish to further explore its potential as new drugs for medical conditions such as protozoal diseases and cancer.

1. Site Directed Mutagenesis to Probe for Active Site Components of Liver Mitochondrial Aldehyde Dehydrogenase.- 2. Substrate Binding Pocket Structure of Human Aldehyde Dehydrogenases: A Substrate Specificity Approach.- 3. Human Class 1 Aldehyde Dehydrogenase: Expression and Site-Directed Mutagenesis.- 4. Nitrate Esters as Inhibitors and Substrates of Aldehyde Dehydrogenase.- 5. Use of a Chromophoric Reporter Group to Probe the Active Site of Cytosolic Aldehyde Dehydrogenase.- 6. Studies of the Esterase Activity of Cytosolic Aldehyde Dehydrogenase Using Sterically Hindered and Cyclic Substrates.- 7. The Reduction of Propionic Anhydride by Aldehyde Dehydrogenase-Nadh Mixtures at pH 7.- 8. Cloning and Characterisation of the cDNA for Sheep Liver Cytosolic Aldehyde Dehydrogenase.- 9. Crystallization of Sheep Liver Cytosolic Aldehyde Dehydrogenase in a Form Suitable for High Resolution X-Ray Structural Analysis.- 10. Progress toward the Tertiary Structure of (Class 3) Aldehyde Dehydrogenase.- 11. UDP-Glucose Dehydrogenase: Structural Characteristics.- 12. Kinetic Studies on Class 3 Aldehyde Dehydrogenase from Bovine Cornea.- 13. Covalent Modification of Class 2 and Class 3 Aldehyde Dehydrogenase by 4-Hydroxynonenal.- 14. Constitutive and Overexpressed Human Cytosolic Class-3 Aldehyde Dehydrogenases in Normal and Neoplastic Cells/Secretions.- 15. Metabolism of Cyclophosphamide by Aldehyde Dehydrogenases.- 16. Tissue-Specific Expression and Preliminary Functional Analysis of the 5? Flanking Regions of the Human Mitochondrial Aldehyde Dehydrogenase (ALDH2) Gene.- 17. Transgenesis of the Aldehyde Dehydrogenase-2 (ALDH2) Locus in a Mouse Model and in Cultured Human Cells.- 18. Class 3 Aldehyde Dehydrogenase: A Northern Perspective in the Land Down Under.- 19. Studies on the Induction of Rat Class 3 Aldehyde Dehydrogenase.- 20. Mouse Class 3 Aldehyde Dehydrogenases.- 21. Cloning and Characterization of Genes Encoding Four Additional Human Aldehyde Dehydrogenase Isozymes.- 22. New Human Aldehyde Dehydrogenases.- 23. Retinoic Acid Synthesizing Enzymes in the Embryonic and Adult Vertebrate.- 24. Retinoic Acid Synthesis in the Developing Spinal Cord.- 25. Structure and Mechanism of Aldehyde Reductase.- 26. Expression of Human and Rat Carbonyl Reductase in E. coli: Comparison of the Recombinant Enzymes.- 27. Molecular Cloning and Sequencing of Mouse Hepatic 11ss-Hydroxysteroid Dehydrogenase/Carbonyl Reductase: A Member of the Short Chain Dehydrogenase Superfamily.- 28. Molecular Modelling Calculations on the Binding of D- and L-Xylose to Wild-Type Aldose Reductase and Its H11OQ and H11OA Mutants.- 29. Stopped-Flow Studies of Human Aldose Reductase Reveal which Enzyme Form Predominates during Steady-State Turnover in Either Reaction direction.- 30. Lysine Residues in the Coenzyme-Binding Region of Mouse Lung Carbonyl Reductase.- 31. Substrate Specificity and Kinetic Mechanism of Tetrahymena 20?-Hydroxysteroid Dehydrogenase.- 32. Purification and Characterization of Recombinant Human Placental and Rat Lens Aldose Reductases Expressed in Escherichia coli.- 33. Rat and Human Bile Acid Binders Are Members of the Monomeric Reductase Gene Family.- 34. The Alcohol Dehydrogenase System.- 35. Promoters of the Mammalian Class III Alcohol Dehydrogenase Genes.- 36. Class I and Class Iv Alcohol Dehydrogenase (Retinol Dehydrogenase) Gene Expression in Mouse Embryos.- 37. Molecular Evolution of Class I Alcohol Dehydrogenases in Primates: Models for Gene Evolution and Comparison of 3? Untranslated Regions of cDNAS.- 38. the Role of Leucine 116 in Determining Substrate Specificity in Human B1 Alcohol Dehydrogenase.- 39. Mutations of Human Class III Alcohol Dehydrogenase.- 40. Human and Rat Class IV Alcohol Dehydrogenases: Correlations of Primary Structures with Enzymatic Properties.- 41. Cloning and Expression of a Human Stomach Alcohol Dehydrogenase Isozyme.- 42. Purification and Properties of Murine Corneal Alcohol Dehydrogenase: Evidence for Class IV ADH P

Rapid progress has been made in our understanding of the molecular mechanisms of cell growth and oncogenesis during the past decade. Special attention has been given to the presentation of the frequently neglected close correlation between changes in signal transduction and metabolic pathways during oncogenesis. This book advances the knowledge of mechanisms regulating metabolism and functioning of vitamin A and offers the most recent results of research on the clinical efficiency of retinoids in skin disorders and cancer. The book presents recent findings on the regulation of cell growth in normal and neoplastic tissues by growth factors including hormones, and by the activation and inactivation of oncogenes and tumor suppressor genes, respectively. It also offers a survey of the molecular and cell biochemistry of retinoids. Basic researchers in biochemistry, pharmacology and cell biology as well as clinicians will find this book very informative and up-to-date. This book advances the knowledge of mechanisms regulating metabolism and functioning of vitamin A and offers the most recent results of research on clinical efficiency of retinoids in skin disorders and cancer. Basic researchers in biochemistry, pharmacology, cell biology, and clinicians will find this book very informative and up-to-date. The chapters, organized in six sections, are contributed by leading scientists who have been working in the retinoid field for decades. Their experience and competence is aknowledged worldwide.

Retinoids have received considerable attention in recent years and due cognizance has been given to their versatility as biological response modifiers, as evidenced by the virtually explosive growth of literature in this field in the past few years. This volume has been designed to give a current state-of-the-art picture of retinoids. The perceived potential of retinoids in the treatment of certain disease stated has initiated attempts at identifying and synthesizing new retinoid derivatives with definable and selective effects on aberrant biological phenomena. Appropriately, therefore, we begin with the chemistry of retinoids and their derivatives together with discussions of their biological activity. Major advances have been made in understanding the mechanisms by which retinoids modulate physiological and phenotypic traits of cells. The transduction of retinoid signaling by the mediation of nuclear receptors of the steroid/thyroid receptor superfamily has now been studied extensively and the cloning and defining the characteristics of these receptors has been a focus of discussion in this volume. Retinoids also markedly modulate the transduction of extracellular signals such as those imparted by growth factors and hormones, and thus actively influence and control cellular proliferative patterns. Retinoids can alter epidermal growth factor receptor expression (Kawaguchi et al., 1994), responsiveness to thyroid hormone (Esfandiari et al., 1994; Pallet et al., 1994), inhibit the proliferative responses of hematopoietic progenitor cells to granulocyte colony stimulating factor (Smeland et al., 1994), and modulate secretion on interleukins by leukaemic cells (Balitrand et al., 1994), among other things. This has obvious implications for pharmacological manipulation of deregulated growth (Dickens and Colletta, 1993; Mulshine et al., 1993). Apoptosis is another component in the regulation of growth control. Apoptotic cell death is influenced by several agents and retinoids may function by interfering with apoptotic pathways of regulation of growth control and quite legitimately, therefore, the importance of this aspect of retinoid function has been duly recognized here.

This issue of Medical Clinics of North America, guest edited by Drs. Douglas Paauw and Kim O'Connor, is devoted to Pharmacologic Therapy. Articles in this issue include: Pharmacologic Therapies for Autoimmune and Rheumatologic Conditions; Pharmacologic Therapies for Ophthalmologic Conditions; Pharmacologic Therapies for Neurologic Conditions; Pharmacologic Therapies for Cardiac Conditions; Pharmacologic Therapies in Men's Health; Pharmacologic Therapies in Anticoagulation; Pharmacologic Therapies in Women's Health: Menopause Treatment and Contraception; Pharmacologic Therapies in GI disease; Pharmacologic Therapies in Pulmonology and Allergy; Pharmacologic Therapies for Substance Abuse; Pharmacologic Therapies in Infectious Disease; Pharmacologic Therapies for HIV; Pharmacologic Therapies in Type 2 DM; Pharmacologic Therapies in Musculoskeletal Conditions; and Osteoporosis Treatment.

For many years, physicians and the public assumed that the discovery of new antimicrobial agents would outpace the ability of bacteria to mutate and develop drug resistance. Yet the development of new antibiotics has not kept up with bacterial evolution, especially since the late 1990's. At that time a multitude of pharmaceutical companies abandoned antibiotic research because of strong economic disincentives. For example, it is challenging for these companies to recuperate the investment (typically in the hundreds of millions of dollars) made in developing a new antibiotic, which is typically prescribed for a few days, compared to drugs that treat chronic conditions like heart disease or mental illness. This situation has led the U.S. federal government to take a more active lead in addressing antibiotic resistance. Recently, the White House announced an action plan that includes improving surveillance, developing better diagnostic tools, accelerating drug development, and improving global coordination of antibiotic resistance issues. Equally important is the $1.2 billion dollars that has been pledged to fund these efforts. While we await the implementation of new policies, this issue of Infectious Disease Clinics of North America brings together leading authorities in the field of antibiotic resistance who discuss current issues including antibiotic stewardship, the changing role of the microbiology laboratory in determining antibiotic resistance in gram-negative pathogens, the continuing spread of metallo-ss-lactamases, ESBLs and KPCs, antibiotic options for treating resistant gram-negative infections such as colistin and tigecycline, resistance mechanisms and new treatment options for Mycobacterium tuberculosis, emerging resistance mechanisms in aminoglycosides, issues with antibiotic resistance in immunocompromised patients, new ss-lactamase inhibitors in the clinic, and resistance in VRE and Staphylococcus aureus. Additionally, combination therapy for resistant gram-negative infections has been advocated by some authorities and the advantages and disadvantages of this strategy will be reviewed.

This issue of Dental Clinics of North America focuses on Pharmacology and Therapeutics for the Dentist. Articles will include: Emergency Drugs for the Dental Office; Oral Sedation for Adult and Pediatric Dental Patients; Update on Analgesic Medication for Adult and Pediatric Dental Patients; Medication Management for TMD/TMJ Dental Patients; Medications and their Role in the Chronic Facial/Neuropathic Pain of Dental Patients; Medication Management for Xerostomia and Glossodynia in the Dental Patient; Update on Topical and Local Anesthesia Agents for Dental Patients; Current Concepts of Prophylactic Antibiotics for Dental Patients; Medication Management of Jaw Lesions for Dental Patients; Current Update on Antibiotic Therapy for Odontogenic Infections in Dental Patients; Review of Top 10 Prescribed Drugs and their Interaction with Dental Treatment; Botox: Review and Its Role in the Dental Office; Medication and the Gravid and Nursing Dental Patient; Conscious IV Sedation in Dentistry: A Review of Current Therapy; Medications to Assist in Tobacco Cessation for the Dental Patient; Topical and Systemic Drugs in the Treatment of Oral Ulcers for the Dental Patient, and more!

"Progress in Medicinal Chemistry" provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.
"Progress in Medicinal Chemistry" provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

This book is a compilation of past and recent knowledge in the field of emerging drug resistance. The book covers major aspects of drug resistance in bacteria, fungi, malaria, and cancer.Human survival on earth is constantly threatened by disease and syndrome. From the early days, the aim of research in medicine was to find therapeutic agents that can improve the quality of human life. Although humans are dependent on natural compounds from early days their dependence of drugs increased excessively in last century. The advances in chemistry and biology have helped researchers to identify the drugs that have improved treatment of many diseases. The primary factor for treatment of these diseases is dependent on the efficacy of drugs available. The development of resistance to these drugs is one of the major hindrances. Although there are number of books available on this topic, "drug resistance" biology across kingdoms has never been discussed in a coherent way.

Reviews current methodology for assessing the health status of patients - their "quality of life" - and shows how this methodology can be applied to specific diseases such as cancer, rheumatoid arthritis, angina and Parkinson's disease. The text includes chapters on the Nottingham health profile, assessing quality of life in major disease areas, the importance of quality of life in policy decisions and development, testing and use of the sickness impact profile.

Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic.

Mechanism of Action and Rationale for the Use of Biological Response Modifiers, Differentiating Agents and Nucleoside Analogues in Combination: Cytokine Synergy in Immunotherapy (J.W. Hadden et al.). Monitoring Combination Therapy Trials (J.L. Rossio et al.). Combination Chemotherapy and BRM Therapy in the Treatment of Cancer: Cancer Immunochemotherapy (G. Graziani et al.). Combination of Chronic Indomethacin and Intermittent IL2 Therapy in the Treatment of Disseminated Cancer (P.K. Lala et al.). Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes (A. Venditti et al.). Single and Combination Therapy with BRM's in the Treatment of Infectious Diseases, AIDS, and Autoimmunity: AntiCytokine Therapy of Murine Candidiasis (L. Romani et al.). The Basic Research and Clinical Application of Thymopeptidin (C.X. Zheng et al.). Combination AntiHIV Therapy (T.C. Merigan). 22 additional articles. Index.

The Guest Editors created a unique focus to the general topic of infectious diseases. They have focused on contemporary management of antibiotics used for procedures and infections. Articles are devoted to:Update on Antibiotic Prophylaxis for GU Procedures in Patients with Arificial Joint Replacement and Artifical Heart Valves; Asymptomatic Bacteriuria; Urinary Tract Infection and Bacteruria in Pregnancy; Resistance Patterns in Contemporary Antibiotics: ESBL and Beyond ; UTI and Neurogenic Bladder; Modern Guidelines for Skin and Bowel Prep for Open and Laparascopic GU Surgery; Work up of Pediatric Urinary Tract Infection; Pre Prostate Biopsy Rectal Culture and Post Biopsy Sepsis; Infection with Foreign Bodies: Mesh and Prostheses; Treatment of the Infected Stone; Sexually Transmitted Infections: Updated Guidelines and Treatment; Bacteruria/UTI in the Elderly; Treatement of Fungal Urinary Tract Infection; and STDs.

This book discusses cancers and the resurgence of public interest in plant-based and herbal drugs. It also describes ways of obtaining anti-cancer drugs from plants and improving their production using biotechnological techniques. It presents methods such as cell culture, shoot and root culture, hairy root culture, purification of plant raw materials, genetic engineering, optimization of culture conditions as well as metabolic engineering with examples of successes like taxol, shikonin, ingenol mebutate and podophylotoxin. In addition, it describes the applications and limitations of large-scale production of anti-cancer compounds using biotechnological means. Lastly, it discusses future economical and eco-friendly strategies for obtaining anti-cancer compounds using biotechnology.